August 2014 Issue of MMM

August 2014 Issue of MMM

August 2014

Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Editor's Desk

We've only just begun

We cemented our credibility during the most difficult period for publishing

Features

Biotech Report: Ultra Man

Innovation is still valued in the orphan-drug space, but the reimbursement bar is rising. NPS Pharma's Eric Pauwels, who's launched five ultra-rare disease products, explains ...

Leadership Exchange: Thinking More Like a Patient

A major information explosion is just the tip of the iceberg in the paradigm shift that is taking place between pharma, marketers and the patients ...

Marketing Research: A Question of Value

When assessing the value of breakthrough drugs, Health Economics & Outcomes Research can help generate the economic profile of a new therapy. Mohan Bala and ...

Therapeutic Focus 2014: Oncology

Immunotherapy is an emerging powerhouse in cancer treatment. Early gains being made in multiple tumor types provide a glimpse of the effectiveness of several agents ...

Multichannel Marketing: At Your Service

Pharma is moving toward a broader treatment paradigm based on providing additional services for patients. Boris Kushkuley describes what the Pill+ model looks like, and ...

MM&M Awards 2014: The Final Cut

More than 100 esteemed industry leaders and thinkers spent several hours discussing, reviewing and scoring around 700 entries to the MM&M Awards. Here are the ...

Headliner: Galderma CEO confronts challenges

Stuart Raetzman, CEO, Galderma Labs

In Focus

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture ...

Partner Forum

Can value vanquish payer pressure?

Pharma cites "payer pressure" as one of its biggest marketing challenges yet struggles to make the "value" case for products. How can it translate market-access ...

Consumer Marketing

DDR on DTC: Linzess

Linzess has been enhanced and reworked to reach self-identified sufferers with its own brand relief story

Washington Insider

Washington Insider: When FDA overstates its case

What happens when it's the FDA—not a medical marketer—that is doing the overstating?

Viewpoint

Saying goodbye to brand standards manuals

Don't waste another minute or dollar on your brand standards manual. It's painfully irrelevant

Private View

Private View: Discussing Women's Health

Dan Chichester, chief creative officer, LLNS

Back Talk

Think you own your brand? Think again

When you have a successful brand, you tamper with it at your peril

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.